Los Angeles Capital Management LLC Purchases 30,290 Shares of DaVita Inc. (NYSE:DVA)

Los Angeles Capital Management LLC increased its position in shares of DaVita Inc. (NYSE:DVA) by 644.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,993 shares of the company’s stock after buying an additional 30,290 shares during the period. Los Angeles Capital Management LLC’s holdings in DaVita were worth $4,831,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in DVA. Vanguard Group Inc. increased its position in DaVita by 2.4% during the 4th quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock valued at $662,161,000 after purchasing an additional 145,711 shares during the period. Invesco Ltd. raised its stake in DaVita by 21.3% in the third quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock worth $157,606,000 after buying an additional 292,767 shares in the last quarter. Gates Capital Management Inc. lifted its holdings in DaVita by 3.1% during the fourth quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock worth $94,895,000 after buying an additional 27,660 shares during the period. 8 Knots Management LLC bought a new stake in DaVita during the 4th quarter valued at $89,504,000. Finally, Lazard Asset Management LLC increased its holdings in shares of DaVita by 8.7% in the 3rd quarter. Lazard Asset Management LLC now owns 845,416 shares of the company’s stock valued at $79,916,000 after acquiring an additional 67,970 shares during the period. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Down 1.4 %

Shares of DVA stock opened at $140.24 on Friday. The stock’s fifty day moving average price is $138.14 and its 200 day moving average price is $125.13. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $147.93. The company has a market cap of $12.30 billion, a price-to-earnings ratio of 15.94, a price-to-earnings-growth ratio of 1.09 and a beta of 0.96.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. The business had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 earnings per share. On average, research analysts expect that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of DaVita stock in a transaction on Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the sale, the director now directly owns 10,954 shares in the company, valued at $1,520,524.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DVA shares. Barclays raised their price objective on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday, May 6th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Finally, Truist Financial boosted their price objective on shares of DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $144.67.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.